EMA Authorised: Imfinzi (durvalumab) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency has authorised Imfinzi (durvalumab) for non-small cell lung cancer. AstraZeneca AB is the marketing authorization holder for this …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: AstraZeneca AB. Decision date: 12/02/2026